NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage biopharmaceutical company developing synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments. The Company’s Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are effective and acting anti-infective molecules produced by white blood cells when defending the body against invading pathogens. In preclinical testing, its Aganocide compounds have demonstrated the ability to destroy bacteria, against which they have been tested. On March 25, 2009, the Company announced that it had entered into an agreement with Galderma S.A. to develop and commercialize its Aganocide compounds.